Search

Your search keyword '"Sun, Zhenchang"' showing total 318 results
Start Over Author "Sun, Zhenchang"
318 results on '"Sun, Zhenchang"'

5. Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy

Author

CHAI Xiaofei, QIAO Honghan, ZHANG Lei, LI Xin, LI Ling, WANG Xinhua, FU Xiaorui, ZHANG Xudong, SUN Zhenchang, NAN Feifei, and ZHANG Mingzhi

Subjects
brentuximab vedotin, antibody-drug conjugate, lymphoma, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objective To retrospectively evaluate the clinical efficacy and safety of brentuximab vedotin(BV) combined with chemotherapy in the treatment of malignant lymphoma. Methods We collected the data of 32 lymphoma patients with CD30-positive status, including 14 cases of Hodgkin's lymphomas, 2 cases of diffuse large B-cell lymphomas, and 16 cases of mature T/NK cell lymphomas. Chemotherapy combined with BV was administered to all patients for a minimum of two cycles. The efficacy of the treatment was evaluated according to Lugano criteria every two cycles. Results Complete response rate and overall response rate after four cycles of treatment were 22% and 50%, respectively. Sixteen cases (50.0%) had grades 1 and 2 toxicity, and 16 cases (50.0%) had grade 3 toxicity or higher. The most common adverse events were neutropenia (50.0%), pneumonia (46.9%), and anemia (43.8%). The most common grade 3 or higher adverse events were pneumonia (18.8%) and febrile neutropenia (12.5%). Four patients discontinued brentuximab vedotin because of severe adverse events. Conclusion BV is effective in treating relapsed and refractory CD30- positive Hodgkin's lymphoma and peripheral T-cell lymphoma, and its overall safety is acceptable.

Published
2023
Full Text
View/download PDF

8. Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.

Author

Hu, Lijuan, primary, Yu, Hui, additional, Mei, Heng, additional, Zou, Dehui, additional, Li, Yaqing, additional, Liao, Danying, additional, Liu, Wei, additional, Xu, Yan, additional, Zhang, Lei, additional, Zhang, Xudong, additional, Sun, Zhenchang, additional, Wang, Xinhua, additional, Wang, Min, additional, You, Fengtao, additional, Meng, Huimin, additional, Wang, Tian, additional, Zhang, Bozhen, additional, Yang, Lin, additional, Zhang, Mingzhi, additional, and Huang, Xiaojun, additional

Published
2024
Full Text
View/download PDF

13. Recurrent PDGFRB mutations in unicentric Castleman disease

Author

Li, Zhaoming, Lan, Xuan, Li, Chaoping, Zhang, Yanjie, Wang, Yingjun, Xue, Weili, Lu, Lisha, Jin, Mengyuan, Zhou, Zhiyuan, Wang, Xinhua, Li, Ling, Zhang, Lei, Li, Xin, Fu, Xiaorui, Sun, Zhenchang, Wu, Jingjing, Zhang, Xudong, Yu, Hui, Nan, Feifei, Chang, Yu, Yan, Jiaqin, Wu, Xiaolong, Wang, Guannan, Zhang, Dandan, Zhang, Yuan, Young, Ken H., and Zhang, Mingzhi

Published
2019
Full Text
View/download PDF

14. Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma

Author

Li, Zhaoming, Zhang, Xudong, Xue, Weili, Zhang, Yanjie, Li, Chaoping, Song, Yue, Mei, Mei, Lu, Lisha, Wang, Yingjun, Zhou, Zhiyuan, Jin, Mengyuan, Bian, Yangyang, Zhang, Lei, Wang, Xinhua, Li, Ling, Li, Xin, Fu, Xiaorui, Sun, Zhenchang, Wu, Jingjing, Nan, Feifei, Chang, Yu, Yan, Jiaqin, Yu, Hui, Feng, Xiaoyan, Wang, Guannan, Zhang, Dandan, Fu, Xuefei, Zhang, Yuan, Young, Ken H., Li, Wencai, and Zhang, Mingzhi

Published
2019
Full Text
View/download PDF

16. Data from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Author

Zhang, Mingzhi, primary, Chen, Dan, primary, Fu, Xiaorui, primary, Meng, Huimin, primary, Nan, Feifei, primary, Sun, Zhenchang, primary, Yu, Hui, primary, Zhang, Lei, primary, Li, Ling, primary, Li, Xin, primary, Wang, Xinhua, primary, Wang, Min, primary, You, Fengtao, primary, Li, Zhaoming, primary, Chang, Yu, primary, Zhou, Zhiyuan, primary, Yan, Jiaqin, primary, Li, Jiwei, primary, Wu, Xiaolong, primary, Wang, Yu, primary, Wang, Yinyan, primary, Xiang, Shufen, primary, Chen, YuSheng, primary, Pan, Guifang, primary, Xu, Hanying, primary, Zhang, Bozhen, primary, and Yang, Lin, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Author

Zhang, Mingzhi, primary, Chen, Dan, primary, Fu, Xiaorui, primary, Meng, Huimin, primary, Nan, Feifei, primary, Sun, Zhenchang, primary, Yu, Hui, primary, Zhang, Lei, primary, Li, Ling, primary, Li, Xin, primary, Wang, Xinhua, primary, Wang, Min, primary, You, Fengtao, primary, Li, Zhaoming, primary, Chang, Yu, primary, Zhou, Zhiyuan, primary, Yan, Jiaqin, primary, Li, Jiwei, primary, Wu, Xiaolong, primary, Wang, Yu, primary, Wang, Yinyan, primary, Xiang, Shufen, primary, Chen, YuSheng, primary, Pan, Guifang, primary, Xu, Hanying, primary, Zhang, Bozhen, primary, and Yang, Lin, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Author

Zhang, Mingzhi, primary, Chen, Dan, primary, Fu, Xiaorui, primary, Meng, Huimin, primary, Nan, Feifei, primary, Sun, Zhenchang, primary, Yu, Hui, primary, Zhang, Lei, primary, Li, Ling, primary, Li, Xin, primary, Wang, Xinhua, primary, Wang, Min, primary, You, Fengtao, primary, Li, Zhaoming, primary, Chang, Yu, primary, Zhou, Zhiyuan, primary, Yan, Jiaqin, primary, Li, Jiwei, primary, Wu, Xiaolong, primary, Wang, Yu, primary, Wang, Yinyan, primary, Xiang, Shufen, primary, Chen, YuSheng, primary, Pan, Guifang, primary, Xu, Hanying, primary, Zhang, Bozhen, primary, and Yang, Lin, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Author

Zhang, Mingzhi, primary, Chen, Dan, primary, Fu, Xiaorui, primary, Meng, Huimin, primary, Nan, Feifei, primary, Sun, Zhenchang, primary, Yu, Hui, primary, Zhang, Lei, primary, Li, Ling, primary, Li, Xin, primary, Wang, Xinhua, primary, Wang, Min, primary, You, Fengtao, primary, Li, Zhaoming, primary, Chang, Yu, primary, Zhou, Zhiyuan, primary, Yan, Jiaqin, primary, Li, Jiwei, primary, Wu, Xiaolong, primary, Wang, Yu, primary, Wang, Yinyan, primary, Xiang, Shufen, primary, Chen, YuSheng, primary, Pan, Guifang, primary, Xu, Hanying, primary, Zhang, Bozhen, primary, and Yang, Lin, primary

Published
2023
Full Text
View/download PDF

21. Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Author

Kong, Xiaoshuang, primary, Zhang, Xudong, additional, Ding, Mengjie, additional, Feng, Xiaoyan, additional, Dong, Meng, additional, Zhang, Lei, additional, Fu, Xiaorui, additional, Li, Ling, additional, Li, Xin, additional, Sun, Zhenchang, additional, Yan, Jiaqin, additional, Wang, Xinhua, additional, Wu, Xiaolong, additional, Chen, Qingjiang, additional, Zhang, Mingzhi, additional, and Zhu, Linan, additional

Published
2023
Full Text
View/download PDF

22. Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma

Author

Lin, Meng, primary, Wu, Xiaolong, additional, Zhang, Lei, additional, Li, Ling, additional, Wang, Xinhua, additional, Fu, Xiaorui, additional, Sun, Zhenchang, additional, Zhang, Xudong, additional, Zhu, Linan, additional, Yu, Hui, additional, Chang, Yu, additional, Nan, Feifei, additional, Yan, Jiaqin, additional, Zhou, Zhiyuan, additional, Shi, Cunzhen, additional, Zhang, Mingzhi, additional, and Li, Xin, additional

Published
2023
Full Text
View/download PDF

24. The Relationship and Clinical Significance of Serum Cytokine Expression Level and Skin Pruritus in Patients with Hodgkin Lymphoma and Angioimmunoblastic T-Cell Lymphoma

Author

Wen, Xin, primary, Yu, Hui, additional, Li, Xin, additional, Zhang, Mingzhi, additional, Zhang, Lei, additional, Li, Ling, additional, Wang, Xinhua, additional, Fu, Xiaorui, additional, Sun, Zhenchang, additional, Zhang, Xudong, additional, Zhu, Linan, additional, Wu, Xiaolong, additional, Yan, Jiaqin, additional, Shi, Cunzhen, additional, and Zhang, Mengjuan, additional

Published
2023
Full Text
View/download PDF

25. A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Author

Zhang, Xudong, primary, Wang, Wenhua, additional, Ma, Shanshan, additional, Fan, Mengke, additional, Zhu, Linan, additional, Zhang, Lei, additional, Li, Xin, additional, Li, Ling, additional, Sun, Zhenchang, additional, Wang, Xinhua, additional, Fu, Xiaorui, additional, Li, Zhaoming, additional, Yan, Jiaqin, additional, and Zhang, Mingzhi, additional

Published
2022
Full Text
View/download PDF

26. Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma

Author

Shi, Zhuangzhuang, primary, Hu, Guoru, additional, Li, Min W, additional, Zhang, Lei, additional, Li, Xin, additional, Li, Ling, additional, Wang, Xinhua, additional, Fu, Xiaorui, additional, Sun, Zhenchang, additional, Zhang, Xudong, additional, Tian, Li, additional, Li, Zhaoming, additional, Chen, Wei-Hua, additional, and Zhang, Mingzhi, additional

Published
2022
Full Text
View/download PDF

30. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

Author

Wang, Xinhua, primary, Zhang, Lei, additional, Liu, Xiangli, additional, Li, Xin, additional, Li, Ling, additional, Fu, Xiaorui, additional, Sun, Zhenchang, additional, Wu, Jingjing, additional, Zhang, Xudong, additional, Yan, Jiaqin, additional, Chang, Yu, additional, Nan, Feifei, additional, Zhou, Zhiyuan, additional, Wu, Xiaolong, additional, Tian, Li, additional, Ma, Minrui, additional, Li, Zhaoming, additional, Yu, Hui, additional, Zhu, Linan, additional, Wang, Yingjun, additional, Shi, Cunzhen, additional, Feng, Xiaoyan, additional, Li, Jiwei, additional, Ding, Mengjie, additional, Zhang, Jieming, additional, Dong, Meng, additional, Xue, Hongwei, additional, Wang, Jinghua, additional, Zou, Liqun, additional, Su, Liping, additional, Wu, Jianqiu, additional, Liu, Lihong, additional, Bao, Huizheng, additional, Zhang, Liling, additional, Guo, Yanzhen, additional, Guo, Shuxia, additional, Lu, Yi, additional, Young, Ken H., additional, Li, Wencai, additional, and Zhang, Mingzhi, additional

Published
2022
Full Text
View/download PDF

33. Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system.

Author

Li, Xingying, Yu, Hui, Fu, Xiaorui, Zhang, Lei, Li, Xin, Li, Ling, Wang, Xinhua, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Wu, Jingjing, Chang, Yu, Yan, Jiaqin, Zhou, Zhiyuan, Nan, Feifei, Wu, Xiaolong, Tian, Li, and Zhang, Mingzhi

Subjects
CENTRAL nervous system, CUTANEOUS T-cell lymphoma, LYMPHOMAS, NON-Hodgkin's lymphoma, SURVIVAL rate, OVERALL survival
Abstract

Extranodal natural killer (NK)/T‐cell lymphoma (NKTL) is a rare non‐Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is no standard treatment. 19 of 414 patients (4.59%) with ENKL followed were diagnosed with CNS involvement between 2006 and 2020. Two patients had primary CNS (PCNS) NKTL, and 17 patients had secondary CNS (SCNS) invasion. A total of 9 patients survived and 10 patients died. The median overall survival time was 55 months, and the median survival time after CNS invasion was 17 months. The 5‐year cumulative survival probability was 45.7%. In conclusion, CNS risk evaluation and prophylaxis treatment can be carried out for patients with NK/T‐cell lymphoma prognostic index risk group III/IV. In terms of treatment, systemic therapy based on methotrexate combined with radiotherapy and intrathecal chemotherapy can be selected. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Author

Zhang, Mingzhi, primary, Chen, Dan, additional, Fu, Xiaorui, additional, Meng, Huimin, additional, Nan, Feifei, additional, Sun, Zhenchang, additional, Yu, Hui, additional, Zhang, Lei, additional, Li, Ling, additional, Li, Xin, additional, Wang, Xinhua, additional, Wang, Min, additional, You, Fengtao, additional, Li, Zhaoming, additional, Chang, Yu, additional, Zhou, Zhiyuan, additional, Yan, Jiaqin, additional, Li, Jiwei, additional, Wu, Xiaolong, additional, Wang, Yu, additional, Wang, Yinyan, additional, Xiang, Shufen, additional, Chen, YuSheng, additional, Pan, Guifang, additional, Xu, Hanying, additional, Zhang, Bozhen, additional, and Yang, Lin, additional

Published
2022
Full Text
View/download PDF

36. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Author

Ma, Xinran, Li, Ling, Zhang, Lei, Fu, Xiaorui, Li, Xin, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Feng, Xiaoyan, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Zhang, Jieming, Li, Zhaoming, and Zhang, Mingzhi

Subjects
safety, Adult, Male, Drug Design, Development and Therapy, Adolescent, Dose-Response Relationship, Drug, Pyridines, efficacy, Antineoplastic Agents, relapsed or refractory diffuse large B-cell lymphoma, Middle Aged, Vascular Endothelial Growth Factor Receptor-2, Drug Administration Schedule, VEGFR-2, Young Adult, Clinical Trial Report, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Prospective Studies, Protein Kinase Inhibitors, apatinib, Aged
Abstract

Xinran Ma,* Ling Li,* Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li, Mingzhi Zhang Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province, Zhengzhou 450002, Henan, People’s Republic of ChinaTel +86-13838565629Email mingzhi_zhang1@163.comPurpose: Treatment options for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) represent an unmet medical need. Apatinib is a new oral tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumour angiogenesis. In the present study, we evaluated the efficacy and safety of apatinib for patients with RR DLBCL.Patients and Methods: In this phase II, open-label, single-arm, prospective study, we enrolled patients aged 14– 70 years with treatment failure of at least two chemotherapeutic regimens using Simon’s two-stage design. All patients were administered apatinib at an initial dose of 500 mg on a 4-week cycle at home and visited the outpatient clinic every two cycles to evaluate efficacy and to record adverse events. We considered objective response rate (ORR) as the primary end point, and progression-free survival (PFS), and overall survival (OS) plus duration of response (DoR) as the secondary end point. (This trial was registered at ClinicalTrials.gov, identifier: NCT03376958.).Results: From January 2017 to February 2019, we screened 35 patients and enrolled 32 eligible patients. At the cutoff point (April 2019), we noted 2 (6.3%) complete responses, 12 (37.5%) partial responses, and 9 (28.1%) stable diseases, attributing to an ORR of 43.8% and a disease control rate of 71.9%. The median PFS and OS were 6.9 (95% confidence interval [CI], 5.8– 7.9) and 7.9 months (95% CI, 7.0– 8.7), respectively. The median DoR was 5.0 months (95% CI, 3.5– 6.5) for patients who achieved PR. The most common grade 3– 4 adverse events (AE) were hypertension (12.6%), hand–foot syndrome (9.4%), and leucopenia (6.3%). No apatinib-related deaths were noted.Conclusion: Home administration of apatinib shows promising efficacy and manageable AEs in patients with RR DLBCL.Keywords: apatinib, relapsed or refractory diffuse large B-cell lymphoma, VEGFR-2, efficacy, safety

Published
2020

37. Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

Author

Ge, Jurui, primary, Xia, Yaqin, additional, Sun, Zhenchang, additional, Zhang, Lei, additional, Li, Xin, additional, Li, Ling, additional, Wang, Xinhua, additional, Zhang, Xudong, additional, Li, Zhaoming, additional, Nan, Feifei, additional, Wan, Wenjuan, additional, Xu, Duo, additional, Ding, Jiayin, additional, Fu, XiaoRui, additional, and Zhang, Mingzhi, additional

Published
2022
Full Text
View/download PDF

39. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients

Author

Zhou, Zhiyuan, Li, Xiang, Chen, Changying, Li, Xin, Zhang, Lei, Li, Ling, Wang, Xinhua, Ma, Wang, Fu, Xiaorui, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Yan, Jiaqin, Chang, Yu, Lu, Lisha, Qin, Beibei, Li, Xiaoli, Wen, Jianguo, and Zhang, Mingzhi

Published
2014
Full Text
View/download PDF

42. Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

Author

Zhang, Lei, primary, Liu, Xiyang, additional, Wang, Xinhua, additional, Chang, Yu, additional, Fu, Xiaorui, additional, Li, Xin, additional, Li, Ling, additional, Yan, Jiaqin, additional, Nan, Feifei, additional, Wu, Xiaolong, additional, Zhu, Linan, additional, Sun, Zhenchang, additional, Yu, Hui, additional, and Zhang, Mingzhi, additional

Published
2021
Full Text
View/download PDF

43. A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Author

Zhang, Mingzhi, primary, Fu, Xiaorui, additional, Meng, Huimin, additional, Wang, Min, additional, Wang, Yu, additional, Zhang, Lei, additional, Li, Ling, additional, Li, Xin, additional, Wang, Xinhua, additional, Sun, Zhenchang, additional, Yu, Hui, additional, Li, Zhaoming, additional, Nan, Feifei, additional, Chang, Yu, additional, Zhou, Zhiyuan, additional, Yan, Jiaqin, additional, Li, Jiwei, additional, Wu, Xiaolong, additional, Pan, Guifang, additional, Zhao, Yanmei, additional, Chen, Yu-Sheng, additional, You, Fengtao, additional, and Yang, Lin, additional

Published
2021
Full Text
View/download PDF

45. The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells

Author

Zhang, Mingzhi, primary, Fu, Xiaorui, additional, Meng, Huimin, additional, Wang, Min, additional, Wang, Yu, additional, Pan, Guifang, additional, Zhang, Lei, additional, Li, Ling, additional, Li, Xin, additional, Wang, Xinhua, additional, Sun, Zhenchang, additional, Yu, Hui, additional, Li, Zhaoming, additional, Nan, Feifei, additional, Chang, Yu, additional, Zhou, Zhiyuan, additional, Yan, Jiaqin, additional, Li, Jiwei, additional, Wu, Xiaolong, additional, Zhao, Yanmei, additional, Chen, Yu-Sheng, additional, You, Fengtao, additional, Chen, Dan, additional, Zhang, Tingting, additional, Zhang, Bozhen, additional, and Yang, Lin, additional

Published
2021
Full Text
View/download PDF

47. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial

Author

Wu, Jingjing, primary, Gao, Fenghua, additional, Wang, Wenhua, additional, Zhang, Xudong, additional, Dong, Meng, additional, Zhang, Lei, additional, Li, Xin, additional, Li, Ling, additional, Sun, Zhenchang, additional, Wang, Xinhua, additional, Fu, Xiaorui, additional, Zhu, Linan, additional, Ding, Mengjie, additional, Niu, Songtao, additional, Li, Zhaoming, additional, Chang, Yu, additional, Nan, Feifei, additional, Yan, Jiaqian, additional, Yu, Hui, additional, Wu, Xiaolong, additional, Zhou, Zhiyuan, additional, Zhang, Jieming, additional, and Zhang, Mingzhi, additional

Published
2021
Full Text
View/download PDF

49. Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

Author

Ma,Qianwen, Chang,Yu, Li,Ling, Li,Xin, Wang,Xinhua, Wu,Jingjing, Fu,Xiaorui, Sun,Zhenchang, Yu,Hui, Zhang,Xudong, Zhou,Zhiyuan, Nan,Feifei, Li,Zhaoming, Liu,Xiyang, Zhao,Qian, Li,Yang, Zhang,Lan, Zhang,Mingzhi, and Zhang,Lei

Subjects
Cancer Management and Research, immune system diseases, R-CHOP, hemic and lymphatic diseases, R-DA-EPOCH, double CNG, DHL, efficacy and prognosis, Original Research
Abstract

Qianwen Ma,1,2,* Yu Chang,1,2,* Ling Li,1,2 Xin Li,1,2 Xinhua Wang,1,2 Jingjing Wu,1,2 Xiaorui Fu,1,2 Zhenchang Sun,1,2 Hui Yu,1,2 Xudong Zhang,1,2 Zhiyuan Zhou,1,2 Feifei Nan,1,2 Zhaoming Li,1,2 Xiyang Liu,1,2 Qian Zhao,1,2 Yang Li,1,2 Lan Zhang,2,3 Mingzhi Zhang,1,2 Lei Zhang1,2 1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, China; 2Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450000, Henan, China; 3Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, China *These authors contributed equally to this work Purpose: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimens in double-hit lymphoma (DHL) and gene copy number gain (CNG) lymphoma and to contrast the prognosis of these two disease types. Methods: We retrospectively examined 127 cases of newly diagnosed diffuse large B-cell lymphoma (DLBCL), and used fluorescence in situ hybridization (FISH) to detect genetic abnormalities in MYC, BCL2, and BCL6. Results: In the two schemes, the 2-year progression-free survival (PFS) was higher for R-DA-EPOCH group than for R-CHOP (79.8% vs 57.5%, P=0.002), this advantage was also reflected in 2-year overall survival (OS) (81.6% vs 58.5%, P=0.002). In double CNG patients, R-DA-EPOCH regimen was significantly better than R-CHOP (P=0.007 for PFS, P=0.010 for OS), and R-DA-EPOCH has the same advantage in DHL patients (P=0.001 for PFS, P=0.047 for OS). For the two disease types, the PFS for DHL was inferior to that for double CNG (52.9% vs 72.4%, P=0.008), while the OS was not significantly different (P=0.050). Subgroup analysis showed that the PFS for double CNG with MYC and BCL2 was superior to that for DHL with MYC and BCL2 (P=0.043), this trend is also seen in double CNG and DHL with MYC and BCL6 (P=0.036). However, the OS was not significantly different between the two subgroups. Multivariate analyses showed that in DLBCL patients with genetic abnormality detected by FISH, the treatment and disease types were independent prognostic factors. The adverse reaction rates were similar in R-DA-EPOCH and R-CHOP (P>0.05). Conclusion: Our retrospective study shows that DHL has a poorer prognosis than double CNG. Based on its improved lifetime and good tolerance, R-DA-EPOCH is a promising regimen for DHL or double CNG, which is expected to become the first-line treatment for high-risk DLBCL types based on more clinical research. Keywords: R-DA-EPOCH, R-CHOP, DHL, double CNG, efficacy and prognosis

Published
2019

50. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma

Author

Feng, Xiaoyan, primary, Wen, Xin, additional, Li, Ling, additional, Sun, Zhenchang, additional, Li, Xin, additional, Zhang, Lei, additional, Wu, Jingjing, additional, Fu, Xiaorui, additional, Wang, Xinhua, additional, Yu, Hui, additional, Ma, Xinran, additional, Zhang, Xudong, additional, Xie, Xinli, additional, Han, Xingmin, additional, and Zhang, Mingzhi, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results